Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Lippincott Williams and Wilkins
Abstract
BACKGROUND: The aim of this study is to analyze polymorphisms in genes involved in 6-mercaptopurine detoxification (TPMT); methotrexate (MTX) metabolism including ABCB1 (or MDR1), ABCC2, SLC19A1 (or RFC1), and SLCO1B1; and the MTX effect mainly MTHFR and TYMS, and to assess whether these polymorphisms are predictors of treatment toxicity and/or MTX clearance. MATERIALS AND METHODS: This study included 127 Lebanese acute lymphoblastic leukemia patients, of whom 117 were treated following the St Jude's Children Research Hospital protocol. Genotyping was performed using real-time PCR or restriction fragment length polymorphism. MTX levels were measured using a polarization fluorescence assay from Roche. MTX clearance was estimated on the basis of all available MTX levels measured after high-dose MTX treatment during the consolidation phase. RESULTS: Five variants in four genes (MTHFR, ABCB1, ABCC2, and TYMS) were shown to be associated with toxicity, but neither was associated with MTX pharmacokinetic parameters. For instance, during the consolidation phase, a statistically significant association was found between MTHFR rs1801133 variant allele carriers and a decrease in hemoglobin levels [odds ratio (OR)=3.057; 95% confidence interval (CI): 1.217; 7.680]. In addition, a statistically significant association was found among neutropenia (absolute neutrophil count<500) and variant allele carriers of ABCB1 rs1045642 (OR=5.174; 95% CI: 1.674; 15.989) and ABCB1 rs1128503 (OR=3.364; 95% CI: 1.257; 9.004), respectively. ABCC2 rs717620 variant allele carriers needed significantly more time to reach a MTX level below 0.1 μmol/l (β=5.122; 95% CI: 1.412; 8.831). During the continuation phase, a statistically significant association was found between ABCC2 rs717620 and TYMS 28-bp tandem repeats carriers with the need to decrease weekly MTX doses (β=-4.905; 95% CI:-9;-0.809 and β=-5.770; 95% CI:-10.138;-1.403), respectively. CONCLUSION: Genotyping for MTHFR, ABCB1, ABCC2, and TYMS polymorphisms may be useful in identifying patients at risk of increased MTX toxicity and the need for dose optimization before treatment initiation. © Lippincott Williams and Wilkins.
Description
Keywords
Acute lymphoblastic leukemia, Genetic polymorphisms, Lebanese, Methotrexate clearance, Toxicity, 6-mercaptopurine, Child, Child, preschool, Female, Genotype, Humans, Infant, Lebanon, Male, Methotrexate, Multidrug resistance-associated proteins, Organic anion transporters, P-glycoprotein, Pharmacogenetics, Polymorphism, genetic, Precursor cell lymphoblastic leukemia-lymphoma, Reduced folate carrier protein, Retrospective studies, Treatment outcome, Cyclophosphamide, Cytarabine, Dexamethasone, Hemoglobin, Mercaptopurine, Vincristine, Abcb1 gene, Abcc2 gene, Allele, Area under the curve, Article, Cancer chemotherapy, Detoxification, Drug clearance, Drug detoxification, Drug dose reduction, Drug megadose, Erythrocyte transfusion, Febrile neutropenia, Fluorescence polarization, Gene, Genetic association, Genetic polymorphism, Genetic variability, Hemoglobin blood level, Human, Induction chemotherapy, Leukocyte count, Major clinical study, Mthfr gene, Neutropenia, Neutrophil count, Oncogene, Patient, Prediction, Priority journal, Real time polymerase chain reaction, Restriction fragment length polymorphism, Side effect, Slc19a1 gene, Slco1b1 gene, Tandem repeat, Tpmt gene, Tyms gene